Headlines about Orexigen Therapeutics (NASDAQ:OREX) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.6839753913345 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Orexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Beats Expectations By $0.78 EPS (americanbankingnews.com)
- BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt (reuters.com)
- Orexigen Therapeutics’ (OREX) CEO Michael Narachi on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Orexigen Therapeutics : reports 3Q loss (4-traders.com)
- Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America (finance.yahoo.com)
A number of research firms have weighed in on OREX. Zacks Investment Research lowered Orexigen Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. ValuEngine lowered Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Orexigen Therapeutics (NASDAQ OREX) traded up $0.11 during mid-day trading on Tuesday, reaching $1.76. The company’s stock had a trading volume of 703,100 shares, compared to its average volume of 328,989. The company has a debt-to-equity ratio of -4.08, a quick ratio of 2.36 and a current ratio of 2.74. Orexigen Therapeutics has a twelve month low of $1.58 and a twelve month high of $5.70.
Orexigen Therapeutics (NASDAQ:OREX) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.78. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 120.77%. The business had revenue of $18.90 million for the quarter, compared to analyst estimates of $24.20 million. During the same quarter last year, the firm posted $1.12 earnings per share. The business’s revenue was up 170.0% compared to the same quarter last year. sell-side analysts predict that Orexigen Therapeutics will post -10.77 earnings per share for the current fiscal year.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.